Clinical Trial Search

Primary: Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15 — 5.83; 6.16; 5.88; -0.77 log 10 IU/mL

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 80.0 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants

Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)12 — 91 percentage of participants — p=< 0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.2 percentage of participants

Primary: Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.6; 100.0; 93.4 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm — 94.0; 96.8; 93.1 percentage of participants

Primary: Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND) — 90.1…

Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 100 percentage of participants

Primary: Sustained Virological Response (SVR) at Week 12 — 116; 66 Participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 89.5; 84.8; 84.0; 90.9 percentage of participants

Primary: Number of Participants With Sustained Virologic Response — 70 Participants

Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 28 Participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 78.6; 58.8; 100.0; 86.7 percentage of…

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 90.9; 95.2; 95.0 percentage of participants

Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 89.5 percentage of participants

Primary: Virological Response (Intention to Treat) — 19; 21; 7; 2 participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 84.0; 70.4; 91.7; 88.9 percentage of participants

Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 71.9; 85.4; 92.9 percentage of participants

Primary: Sustained Virologic Response — 87; 117 participants — p=< 0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 80 percentage of participants

Primary: Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2 — 100; 95.8 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN…

Primary: Sustained Virologic Response (SVR) — 10; 10 Participants

Primary: Number of Participants With Adverse Events (AEs) — 67; 36; 71; 68 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.0; 100.0; 100.0; 93.3 percentage of participants